感染症と治療ジャーナル

抽象的な

A Search for the Risk Factors for Daptomycin-Rifampin-Induced Rhabdomyolysis, Liver Injury and Acute Kidney Injury

Venu M Ganipisetti, Anand Athavale

The Infectious Diseases Society of America recommends daptomycin as one of the antibiotics for treating Methicillin-Resistant Staphylococcus aureus (MRSA) bone and joint infections and native valve infective endocarditis. The addition of rifampin may be particularly beneficial in cases of prosthetic joint infections due to rifampin's biofilm-disrupting properties, excellent bone penetration, and ability to prevent the emergence of resistance. However, safety data on the combination regimen is limited, and clinicians must be aware of potential adverse effects. We recently encountered a case of simultaneous rhabdomyolysis, acute renal failure, and hepatic injury associated with a Daptomycin-Rifampin regimen. In this report, we summarized the possible risk factors for these adverse events based on our extensive literature search and aim to contribute to the identification of at-riskpopulations for future studies.